the public record, side by side

Lamictal (lamotrigine) vs lithium

Lamictal and lithium, compared on what the public record actually supports: side effects by rate from each FDA label, what the largest trial comparison found, who takes each one, who pays, what the labels warn, and what the litigation record holds. Sources on every number.

the short answer

  • is Lamictal or lithium more effective? there is no head-to-head trial record in our library that settles this pair, and we do not fill the gap with a guess. what can be compared is below: each label's own side-effect table, who takes each drug, who pays, and the legal record.
  • which has fewer side effects? the labels say their trials “cannot be directly compared”, because each drug was tested in different people under different rules. what each label prints: Lamictal (lamotrigine): 13% stopped for an adverse reaction vs 16% on placebo (Lamictal label, SPL version 45, effective 2025-10-10). lithium: the label prints no discontinuation rate in the section we transcribed.
  • which should i take? not a question this page answers. the odds ratios are averages across thousands of strangers; your history, other medications and what you can live with are not in them. the questions for your prescriber below are built from what is on this page.

What this page will not do is rank them. These drugs are in different classes and were tested for partly different things, so a single-axis ranking would be a category error. Which one fits you turns on your history, your other medications, and side-effect trade-offs — a prescriber conversation. This page arms that conversation; here are the questions worth taking into it →

side effects by rate: what each label prints, not a head-to-head trial

the labels' own warning, first: “Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.” the two columns below come from different trials, in different people, under different inclusion rules. read each against its own placebo column, not against the other drug.

the two labels list fewer than three reactions under the same name, so there is no side-by-side table here; each label's full table is on the tool page linked below.

  • Lamictal (lamotrigine): 13% stopped for an adverse reaction vs 16% on placebo (Lamictal label, SPL version 45, effective 2025-10-10).
  • lithium: the label prints no discontinuation rate in the section we transcribed.
what makes each table, in the labels' words
  • Lamictal (lamotrigine), SPL version 45, effective 2025-10-10, 6 ADVERSE REACTIONS / 6.1 Clinical Trials Experience, tablets, tablets for oral suspension, and ODT orally disintegrating tablets (LAMICTAL XR is a separate label, not used here). inclusion rule: “Adverse reactions that occurred in at least 5% of patients treated with LAMICTAL and at a greater incidence than placebo. (Table 12, footnote a.)” trials: “The most common adverse reactions seen in association with the use of LAMICTAL as monotherapy (100 to 400 mg/day) in adult patients (aged 18 to 82 years) with bipolar disorder in the 2 double-blind, placebo-controlled trials of 18 months' duration are included in Table 12. Table 12 footnote b: "Patients in these trials were converted to LAMICTAL (100 to 400 mg/day) or placebo monotherapy from add-on therapy with other psychotropic medications. Patients may have reported multiple adverse reactions during the trial; thus, patients may be included in more than 1 category."” DailyMed
  • Eskalith/Lithobid era brands; current generic label used (see source) (lithium carbonate), SPL version 13, effective 2025-12-23, 6 ADVERSE REACTIONS / 6.1 Clinical Trials Experience, lithium carbonate capsules, USP (150 mg, 300 mg, 600 mg) — immediate release; Lithobid extended-release is a separate label, not used here. inclusion rule: “Adverse reactions associated with the use of lithium (incidence of 2% or greater, rounded to the nearest percent, and lithium incidence greater than placebo) that occurred during acute therapy (up to 8-weeks in pediatric patients with bipolar disorder) are shown in Table 3.” trials: “Bipolar I Disorder: The following findings are based on an 8-week, placebo-controlled study for acute manic or mixed episodes of bipolar I disorder in pediatric patients 7 to 17 years (N= 81) [sic — spacing as printed]. In this study, lithium was administered at daily doses ranging from 300 to 3600 (mean dose 1483 mg ± 584) with serum levels ranging from 0 to 2 (mean level 0.98 mEq/L ± 0.47) [sic — units printed only inside the parentheticals]. "Common Adverse Reactions (incidence ≥ 5% and at least twice the rate of placebo): nausea/vomiting, polyuria, thyroid abnormalities, tremor, thirst/polydipsia, dizziness, rash/dermatitis, ataxia/gait disturbance, decreased appetite, and blurry vision."” DailyMed

every row above was transcribed from the current FDA label on 2026-09-08; the full tables, including the reactions only one label lists, are on side-effect rates, drug vs placebo. the sexual side-effect rows carry each label's own underreporting caveat on the SSRI sexual side effects page.

lamotrigine (Lamictal)

mood stabilizer (bipolar maintenance)

FDA approval
2003 — the bipolar-maintenance approval; the epilepsy approval came earlier · full approval journey →
Who takes it (US, 2024)
2,474,525 patients · 12,624,285 prescriptions (AHRQ MEPS)2014 → 2024: 12,705,157 → 12,624,285 prescriptions; the change is within the survey’s margin of errorCorrection (29 September 2026): An earlier version of this section took its numbers from ClinCalc DrugStats, a third-party site that republishes this survey; we now compute them from AHRQ’s public-use files ourselves. It said prescriptions were down 1% since 2014; that change is within the survey’s margin of error, so we no longer state a direction.
Who pays (2024)
Medicare: 4,395,266 claims · 679,206 beneficiariesMedicaid: ≥4,511,361 prescriptionsCommercial claims: not published in any public dataset — a real absence, not a zero.
Boxed warning
Yes — on the current FDA label. read it in context →
Adverse-event reports (FAERS)
Caveat first: FAERS counts unverified REPORTS, not patients or rates — no denominator, and attention inflates reporting. Never compare these counts head-to-head; a longer-marketed, more-prescribed drug accumulates more reports by exposure alone. how to read FAERS →71,378 all-time reports; most-reported terms: drug ineffective, seizure, toxicity to various agents
Legal & safety record
no dedicated record page yet; the journey page carries label history

lithium (lithium)

mood stabilizer

FDA approval
1970 · full approval journey →
Who takes it (US, —)
No year from 2014 to 2024 meets AHRQ’s reliability rule for this drug, so we print no count. Years not shown, under AHRQ’s reliability rule: 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2022, 2023, 2024 (fewer than 60 survey respondents); 2021 (AHRQ masks the name in the public file).Correction (29 September 2026): An earlier version of this section took its numbers from ClinCalc DrugStats, a third-party site that republishes this survey; we now compute them from AHRQ’s public-use files ourselves. It showed 501,291 people and 3,301,040 prescriptions for 2024. No year meets AHRQ’s reliability rule for this drug, so that count is removed. It said prescriptions were down 19% since 2014; too few years meet the rule to show a trend, so that line is removed.
Who pays (2024)
Medicare: 1,140,044 claims · 163,602 beneficiariesMedicaid: ≥1,125,775 prescriptionsCommercial claims: not published in any public dataset — a real absence, not a zero.
Boxed warning
Yes — on the current FDA label. read it in context →
Adverse-event reports (FAERS)
Caveat first: FAERS counts unverified REPORTS, not patients or rates — no denominator, and attention inflates reporting. Never compare these counts head-to-head; a longer-marketed, more-prescribed drug accumulates more reports by exposure alone. how to read FAERS →42,306 all-time reports; most-reported terms: toxicity to various agents, drug ineffective, tremor
Legal & safety record
no dedicated record page yet; the journey page carries label history

questions for your prescriber, built from this page

this page does not tell you to start, stop or switch anything. it arms the conversation where that decision belongs. take these in:

  1. which of Lamictal and lithium did you have in mind first, and what in my history points that way?
  2. these two are different classes (mood stabilizer (bipolar maintenance); mood stabilizer). what are they each being asked to do for me, and is that use on the label or off it?
  3. the label lists these reactions above placebo for the one you're suggesting. which of them should i expect in the first weeks, and which would make you want to hear from me the same day?
  4. how long were the approval trials, and what do we know past that point?
  5. how will we judge whether it is working, by when, and what is the plan if it isn't?
  6. if i ever want to come off it, how is that done, and over how long?
  7. is there a cheaper generic or a formulation that changes the dosing, and does my insurance prefer one of these two?

the longer checklist, for any antidepressant, is questions to ask before starting antidepressants. if you are already on one and it feels like it stopped working, that has its own page.

What the warnings mean, drug by drug

Each explainer reads one drug's current FDA label and the studies in our library, in both directions: the boxed warnings with the label's own numbers, the trials behind the approval and how long they ran, side effects by rate, and the research since.

Questions people search

Is Lamictal or lithium better?

No honest page can answer that in one line. Head-to-head differences between comparable psychiatric medications are usually smaller than rankings suggest, and which fits you depends on your history, other medications, and side-effect trade-offs, a prescriber conversation. What can be compared is the public record (usage, payers, label warnings, approval history, litigation), which is what this page does, with sources.

Is Lamictal the same as lamotrigine, and lithium the same as lithium?

Lamictal is a brand name for lamotrigine. lithium is sold under its generic name. lamotrigine is a mood stabilizer (bipolar maintenance); lithium is a mood stabilizer. This page uses the generic names because the federal datasets do.

Which has fewer side effects, Lamictal or lithium?

The two FDA labels cannot be compared head to head, in their own words, because each drug's trials ran in different people under different rules. What each label prints: Lamictal (lamotrigine): 13% stopped for an adverse reaction vs 16% on placebo (Lamictal label, SPL version 45, effective 2025-10-10). lithium: the label prints no discontinuation rate in the section we transcribed. The page shows the reactions both labels list, each against its own placebo column.

Which is prescribed more, Lamictal or lithium?

The page shows federal survey estimates we compute from AHRQ’s Medical Expenditure Panel Survey public-use files for both lamotrigine and lithium: patients and prescriptions in the latest reliable year, and the yearly series from 2014 where AHRQ’s reliability rule allows it, with a direction stated only when the change is larger than the survey’s margin of error. Prescription volume reflects habits, prices, and marketing as much as evidence, so it is context, not a verdict.

Where these numbers come from

  • Patients and prescriptions: computed by us from AHRQ's public-use Medical Expenditure Panel Survey Prescribed Medicines files, 2014 (HC-168A) to 2024 (HC-254A), with AHRQ's reliability rule (a year with fewer than 60 respondents or a relative standard error over 50% is not shown) — counts of people filling prescriptions, not outcomes. A direction is stated only when the change is larger than the survey's margin of error. Until 29 September 2026 these came from ClinCalc DrugStats, a third-party site; see the correction under each drug where a figure changed.
  • Medicare/Medicaid: CMS public datasets; commercial insurance publishes no per-drug series, so it renders as an absence, never a synthesized number.
  • Label facts: the drugs' current FDA labels via DailyMed — quoted in context on each drug's approval-journey page.
  • FAERS: openFDA — reports, never rates; the caveat travels above every count.
  • Litigation: court records and regulator documents only, on the linked record pages; settled is never adjudicated.

Explore both drugs in depth: /m/lamotrigine · /m/lithium · or the whole library →